Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review

References

• GilmerTHenwoodBMcGovernNHurstSBurgdorfJInnes-GombergDHealth outcomes and costs associated with the provision of culturally competent services for underrepresented ethnic populations with severe mental illnessAdm Policy Ment Health2017 Epub201713
   PubMed Web of Science ®Google Scholar
• ZhaiJGuoXChenMZhaoJSuZAn investigation of economic costs of schizophrenia in two areas of ChinaInt J Ment Health Syst2013712624237846
   PubMed Web of Science ®Google Scholar
• De HertMThysEBoydensJHealth care expenditure on schizophrenia patients in BelgiumSchizophr Bull19982445195279853786
   PubMed Web of Science ®Google Scholar
• LaursenTMMuslinerKLBenrosMEVestergaardMMunk-OlsenTMortality and life expectancy in persons with severe unipolar depressionJ Affect Disord201619320320726773921
   PubMed Web of Science ®Google Scholar
• LaursenTMLife expectancy among persons with schizophrenia or bipolar affective disorderSchizophr Res20111311–310110421741216
   PubMed Web of Science ®Google Scholar
• KishimotoTAgarwalVKishiTLeuchtSKaneJMCorrellCURelapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychoticsMol Psychiatry2013181536622124274
   PubMed Web of Science ®Google Scholar
• IfteniPMogaMABurteaVCorrellCUSchizophrenia relapse after stopping olanzapine treatment during pregnancy: a case reportTher Clin Risk Manag20141090190425364259
   PubMed Web of Science ®Google Scholar
• BortolatoBCarvalhoAFMcIntyreRSCognitive dysfunction in major depressive disorder: a state-of-the-art clinical reviewCNS Neurol Disord Drug Targets201413101804181825470396
   PubMed Web of Science ®Google Scholar
• BortolatoBMiskowiakKWKohlerCAVietaECarvalhoAFCognitive dysfunction in bipolar disorder and schizophrenia: a systematic review of meta-analysesNeuropsychiatr Dis Treat2015113111312526719696
   PubMed Web of Science ®Google Scholar
• BortolatoBMiskowiakKWKohlerCACognitive remission: a novel objective for the treatment of major depression?BMC Med201614926801406
   PubMed Web of Science ®Google Scholar
• MadreMCanales-RodriguezEJOrtiz-GilJNeuropsychological and neuroimaging underpinnings of schizoaffective disorder: a systematic reviewActa Psychiatr Scand20161341163027028168
   PubMed Web of Science ®Google Scholar
• BoraEAkdedeBBAlptekinKThe relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysisPsychol Med20174761030104028032535
   PubMed Web of Science ®Google Scholar
• SoleBVietaEMartinez-AranAThinking ahead: executive dysfunction in bipolar disorderEur Neuropsychopharmacol20162681348134927265034
   PubMed Web of Science ®Google Scholar
• LeuchtSTardyMKomossaKAntipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysisLancet201237998312063207122560607
   PubMed Web of Science ®Google Scholar
• ZhouXKeitnerGIQinBAtypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysisInt J Neuropsychopharmacol20151811yv060
   Web of Science ®Google Scholar
• FountoulakisKNYathamLGrunzeHThe International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 2: review, grading of the evidence, and a precise algorithmInt J Neuropsychopharmacol2017202121179
   PubMed Web of Science ®Google Scholar
• TaylorDMCorneliusVSmithLYoungAHComparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysisActa Psychiatr Scand2014130645246925283309
   PubMed Web of Science ®Google Scholar
• YildizANikodemMVietaECorrellCUBaldessariniRJA network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar maniaPsychol Med201545229931725036226
   PubMed Web of Science ®Google Scholar
• GreenblattHKGreenblattDJUse of antipsychotics for the treatment of behavioral symptoms of dementiaJ Clin Pharmacol20165691048105726953213
   PubMed Web of Science ®Google Scholar
• FarlowMRShamliyanTABenefits and harms of atypical antipsychotics for agitation in adults with dementiaEur Neuropsychopharmacol201727321723128111239
   PubMed Web of Science ®Google Scholar
• MaHHuangYCongZThe efficacy and safety of atypical antipsychotics for the treatment of dementia: a meta-analysis of randomized placebo-controlled trialsJ Alzheimers Dis201442391593725024323
   PubMed Web of Science ®Google Scholar
• MaherARMaglioneMBagleySEfficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysisJAMA2011306121359136921954480
   PubMed Web of Science ®Google Scholar
• AltamuraACDragognaFShould the term ‘antipsychotic’ be changed to ‘multidimensional stabiliser’ in bipolar disorder? Towards a new denomination for ‘atypical antipsychotics’Aust N Z J Psychiatry201347870770923728532
   PubMed Web of Science ®Google Scholar
• DelayJDenikerPRopertRQuatre années d’expérience de la chlorpromazine dans le traitement des psychoses [Four years of experience with chlorpromazine in therapy of psychoses]Presse Med1956642249349613335815
   PubMed Web of Science ®Google Scholar
• BrillNQKoeglerRREpsteinLJForgyEWControlled study of psychiatric outpatient treatmentArch Gen Psychiatry19641058159514159259
   PubMed Web of Science ®Google Scholar
• BuoliMKahnRSSeratiMAltamuraACCahnWHaloperidol versus second-generation antipsychotics in the long-term treatment of schizophreniaHum Psychopharmacol201631432533127297936
   PubMed Web of Science ®Google Scholar
• AltamuraACBuoliMMauriMCHaloperidol versus second-generation antipsychotics in the long-term treatment of schizophrenia: a 4-year follow-up naturalistic studyJ Clin Psychopharmacol201131566166321881452
   PubMed Web of Science ®Google Scholar
• LeuchtSCiprianiASpineliLComparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisLancet2013382989695196223810019
   PubMed Web of Science ®Google Scholar
• HippiusHA historical perspective of clozapineJ Clin Psychiatry199960suppl 122223
   PubMedGoogle Scholar
• GerlachJKoppelhusPHelwegEMonradAClozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophreniaActa Psychiatr Scand19745044104244153596
   PubMed Web of Science ®Google Scholar
• VorugantiLNHeslegraveRJAwadAGQuality of life measurement during antipsychotic drug therapy of schizophreniaJ Psychiatry Neurosci19972242672749262049
   PubMed Web of Science ®Google Scholar
• MortimerAMAl-AgibAOQuality of life in schizophrenia on conventional versus atypical antipsychotic medication: a comparative cross-sectional studyInt J Soc Psychiatry20075329910717472084
   PubMed Web of Science ®Google Scholar
• LiQXiangYTSuYAAntipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: findings of the third national survey on use of psychotropic medications in ChinaAust N Z J Psychiatry201549212913624923760
   PubMed Web of Science ®Google Scholar
• Rauly-LestienneIBoutet-RobinetEAilhaudMCNewman-TancrediACussacDDifferential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist propertiesNaunyn Schmiedebergs Arch Pharmacol20073761–29310517786406
   PubMed Web of Science ®Google Scholar
• CorrellCUFrom receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychoticsEur Psychiatry201025suppl 2S12S2120620881
   PubMed Web of Science ®Google Scholar
• VancampfortDStubbsBMitchellAJRisk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysisWorld Psychiatry201514333934726407790
   PubMed Web of Science ®Google Scholar
• KagalUATorgalSSPatilNMMalleshappaAPrevalence of the metabolic syndrome in schizophrenic patients receiving second-generation antipsychotic agents – a cross-sectional studyJ Pharm Pract201225336837322551560
   PubMedGoogle Scholar
• CorrellCUFredericksonAMKaneJMManuPDoes antipsychotic polypharmacy increase the risk for metabolic syndrome?Schizophr Res2007891–39110017070017
   PubMed Web of Science ®Google Scholar
• CorrellCUDetrauxJDe LepeleireJDe HertMEffects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorderWorld Psychiatry201514211913626043321
   PubMed Web of Science ®Google Scholar
• ZdanysKFCarvalhoAFTampiRRSteffensDCThe treatment of behavioral and psychological symptoms of dementia: weighing benefits and risksCurr Alzheimer Res201613101124113327160166
   PubMed Web of Science ®Google Scholar
• DengCEffects of antipsychotic medications on appetite, weight, and insulin resistanceEndocrinol Metab Clin North Am201342354556324011886
   PubMed Web of Science ®Google Scholar
• VancampfortDCorrellCUGallingBDiabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysisWorld Psychiatry201615216617427265707
   PubMed Web of Science ®Google Scholar
• HillMCrumlishNWhittyPNonadherence to medication four years after a first episode of psychosis and associated risk factorsPsychiatr Serv201061218919220123826
   PubMed Web of Science ®Google Scholar
• PoggeDLSingerMBHarveyPDRates and predictors of adherence with atypical antipsychotic medication: a follow-up study of adolescent inpatientsJ Child Adolesc Psychopharmacol200515690191216379510
   PubMed Web of Science ®Google Scholar
• KarowACzekallaJDittmannRWAssociation of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophreniaJ Clin Psychiatry2007681758017284133
   PubMed Web of Science ®Google Scholar
• MorkenGWidenJHGraweRWNon-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophreniaBMC Psychiatry200883218447935
   PubMed Web of Science ®Google Scholar
• DiMascioAShaderRIHarmatzGSBehavioral toxicity of psychotropic drugs. V. Effects on gross behavior patternsConn Med19693342792815798025
   PubMedGoogle Scholar
• DiMascioAShaderRIBehavioral toxicity of psychotropic drugs. I. Definition. II. Toxic effects on psychomotor functionsConn Med19683286176205674945
   PubMedGoogle Scholar
• DiMascioAGillerDRShaderRIBehavioral toxicity of psychotropic drugs. 3. Effects on perceptual and cognitive functions. IV. Effects on emotional (mood) statesConn Med196832107717754879067
   PubMedGoogle Scholar
• FavaGACosciFOffidaniEGuidiJBehavioral toxicity revisited: iatrogenic comorbidity in psychiatric evaluation and treatmentJ Clin Psychopharmacol201636655055327631576
   PubMed Web of Science ®Google Scholar
• FavaGATossaniEBechPEmerging clinical trends and perspectives on comorbid patterns of mental disorders in researchInt J Methods Psychiatr Res201423suppl 19210124375537
   PubMed Web of Science ®Google Scholar
• RiedelMSchmitzMOstergaardPKComparison of the effects of quetiapine extended-release and quetiapine immediate-release on cognitive performance, sedation and patient satisfaction in patients with schizophrenia: a randomised, double-blind, crossover study (eXtRa)Schizophr Res20151621–316216825592805
   PubMed Web of Science ®Google Scholar
• CitromeLActivating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder: absolute risk increase and number needed to harmJ Clin Psychopharmacol201737213814728141623
   PubMed Web of Science ®Google Scholar
• MeduriMGregoraciGBaglivoVBalestrieriMIsolaMBrambillaPA meta-analysis of efficacy and safety of aripiprazole in adult and pediatric bipolar disorder in randomized controlled trials and observational studiesJ Affect Disord201619118720826674213
   PubMed Web of Science ®Google Scholar
• ZhangJPGallegoJARobinsonDGMalhotraAKKaneJMCorrellCUEfficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysisInt J Neuropsychopharmacol20131661205121823199972
   PubMed Web of Science ®Google Scholar
• BabinSLHoodAJWassefAAWilliamsNGPatelSSSerenoABEffects of haloperidol on cognition in schizophrenia patients depend on baseline performance: a saccadic eye movement studyProg Neuropsychopharmacol Biol Psychiatry20113571753176421689713
   PubMed Web of Science ®Google Scholar
• TakeuchiHSuzukiTRemingtonGEffects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot studySchizophr Bull201339599399823821768
   PubMed Web of Science ®Google Scholar
• SakuraiHBiesRRStroupSTDopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE dataSchizophr Bull201339356457422290266
   PubMed Web of Science ®Google Scholar
• TrampushJWLenczTDeRossePRelationship of cognition to clinical response in first-episode schizophrenia spectrum disordersSchizophr Bull20154161237124726409223
   PubMed Web of Science ®Google Scholar
• RoblesOZabalaABombinICognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosisSchizophr Bull201137240541519706697
   PubMed Web of Science ®Google Scholar
• KomossaKRummel-KlugeCSchwarzSRisperidone versus other atypical antipsychotics for schizophreniaCochrane Database Syst Rev20111
   PubMed Web of Science ®Google Scholar
• Asenjo LobosCKomossaKRummel-KlugeCClozapine versus other atypical antipsychotics for schizophreniaCochrane Database Syst Rev201011
   PubMed Web of Science ®Google Scholar
• KomossaKRummel-KlugeCHungerHOlanzapine versus other atypical antipsychotics for schizophreniaCochrane Database Syst Rev20103
   Web of Science ®Google Scholar
• ZhouZZhuHChenLEffect of aripiprazole on mismatch negativity (MMN) in schizophreniaPLoS One201381e5218623308105
   PubMed Web of Science ®Google Scholar
• CitromeLOtaANagamizuKPerryPWeillerEBakerRAThe effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory studyInt Clin Psychopharmacol201631419220126963842
   PubMed Web of Science ®Google Scholar
• KhannaPSuoTKomossaKAripiprazole versus other atypical antipsychotics for schizophreniaCochrane Database Syst Rev20141
   Web of Science ®Google Scholar
• ManuPDimaLShulmanMVancampfortDDe HertMCorrellCUWeight gain and obesity in schizophrenia: epidemiology, pathobiology, and managementActa Psychiatr Scand201513229710826016380
   PubMed Web of Science ®Google Scholar
• De HertMYuWDetrauxJSweersKvan WinkelRCorrellCUBody weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysisCNS Drugs201226973375922900950
   PubMed Web of Science ®Google Scholar
• De HertMDetrauxJvan WinkelRYuWCorrellCUMetabolic and cardiovascular adverse effects associated with antipsychotic drugsNat Rev Endocrinol20118211412622009159
   PubMed Web of Science ®Google Scholar
• RobinsonDGGallegoJAJohnMA randomized comparison of aripiprazole and risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3-month outcomesSchizophr Bull20154161227123626338693
   PubMed Web of Science ®Google Scholar
• LakkaHMLaaksonenDELakkaTAThe metabolic syndrome and total and cardiovascular disease mortality in middle-aged menJAMA2002288212709271612460094
   PubMed Web of Science ®Google Scholar
• MaayanLCorrellCUManagement of antipsychotic-related weight gainExpert Rev Neurother20101071175120020586697
   PubMed Web of Science ®Google Scholar
• StubbsBWilliamsJGaughranFCraigTHow sedentary are people with psychosis? A systematic review and meta-analysisSchizophr Res20161711–310310926805414
   PubMed Web of Science ®Google Scholar
• MisawaFShimizuKFujiiYIs antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects? A cross-sectional studyBMC Psychiatry20111111821791046
   PubMed Web of Science ®Google Scholar
• Rummel-KlugeCKomossaKSchwarzSSecond-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisonsSchizophr Bull201238116717720513652
   PubMed Web of Science ®Google Scholar
• LaoKSHeYWongICBesagFMChanEWTolerability and safety profile of cariprazine in treating psychotic disorders, bipolar disorder and major depressive disorder: a systematic review with meta-analysis of randomized controlled trialsCNS Drugs201630111043105427550371
   PubMed Web of Science ®Google Scholar
• GaoKKempDEGanocySJGajwaniPXiaGCalabreseJRAntipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic reviewJ Clin Psychopharmacol200828220320918344731
   PubMed Web of Science ®Google Scholar
• RapoportASteinDGrinshpoonAElizurAAkathisia and pseudo-akathisia: clinical observations and accelerometric recordingsJ Clin Psychiatry199455114734777989279
   PubMed Web of Science ®Google Scholar
• Havaki-KontaxakiBJKontaxakisVPChristodoulouGNPrevalence and characteristics of patients with pseudoakathisiaEur Neuropsychopharmacol200010533333610974603
   PubMed Web of Science ®Google Scholar
• CorrellCULeuchtSKaneJMLower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studiesAm J Psychiatry2004161341442514992963
   PubMed Web of Science ®Google Scholar
• O’BrienAComparing the risk of tardive dyskinesia in older adults with first-generation and second-generation antipsychotics: a systematic review and meta-analysisInt J Geriatr Psychiatry201631768369326679687
   PubMed Web of Science ®Google Scholar
• CavazzoniPABergPHKryzhanovskayaLAComparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trialsJ Clin Psychiatry200667110711316426096
   PubMed Web of Science ®Google Scholar
• BoboWVSheltonRCRisperidone long-acting injectable (Risperdal Consta(R)) for maintenance treatment in patients with bipolar disorderExpert Rev Neurother201010111637165820977322
   PubMed Web of Science ®Google Scholar
• OnoSSuzukiYShindoMImprovement of tardive dyskinesia and dystonia associated with aripiprazole following a switch to quetiapine: case report and review of the literatureJ Clin Pharm Ther201237337037222023382
   PubMed Web of Science ®Google Scholar
• TiwariAKZaiCCLikhodiOAssociation study of cannabinoid receptor 1 (CNR1) gene in tardive dyskinesiaPharmacogenomics J201212326026621266946
   PubMed Web of Science ®Google Scholar
• FedorenkoOYLoonenAJLangFAssociation study indicates a protective role of phosphatidylinositol-4-phosphate-5-kinase against tardive dyskinesiaInt J Neuropsychopharmacol2014186
   PubMed Web of Science ®Google Scholar
• MasSGassoPLafuenteAPharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genesPharmacogenomics J201616543944527272046
   PubMed Web of Science ®Google Scholar
• AchaliaRMChaturvediSKDesaiGRaoGNPrakashOPrevalence and risk factors associated with tardive dyskinesia among Indian patients with schizophreniaAsian J Psychiatr20149313524813033
   PubMedGoogle Scholar
• OosthuizenPPEmsleyRAMaritzJSTurnerJAKeyterNIncidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidolJ Clin Psychiatry20036491075108014628983
   PubMed Web of Science ®Google Scholar
• CaligiuriMPLacroJPRockwellEMcAdamsLAJesteDVIncidence and risk factors for severe tardive dyskinesia in older patientsBr J Psychiatry19971711481539337951
   PubMed Web of Science ®Google Scholar
• BergenJKitchinRBerryGPredictors of the course of tardive dyskinesia in patients receiving neurolepticsBiol Psychiatry19923275805941360260
   PubMed Web of Science ®Google Scholar
• WoernerMGCorrellCUAlvirJMGreenwaldBDelmanHKaneJMIncidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naive patientsNeuropsychopharmacology20113681738174621508932
   PubMed Web of Science ®Google Scholar
• LertxundiUHernandezRMedranoJDomingo-EchaburuSGarciaMAguirreCAntipsychotics and seizures: higher risk with atypicals?Seizure201322214114323146619
   PubMed Web of Science ®Google Scholar
• HaddadPMSharmaSGAdverse effects of atypical antipsychotics: differential risk and clinical implicationsCNS Drugs2007211191193617927296
   PubMed Web of Science ®Google Scholar
• WuCSWangSCYehIJLiuSKComparative risk of seizure with use of first- and second-generation antipsychotics in patients with schizophrenia and mood disordersJ Clin Psychiatry2016775e573e57927249081
   PubMed Web of Science ®Google Scholar
• WitkinJMLevantBZapataAKaminskiRGasiorMThe dopamine D3/D2 agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin -9-ol)] protects against acute and cocaine-kindled seizures in mice: further evidence for the involvement of D3 receptorsJ Pharmacol Exp Ther2008326393093818566292
   PubMed Web of Science ®Google Scholar
• BlomMTCohenDSeldenrijkABrugada syndrome ECG is highly prevalent in schizophreniaCirc Arrhythm Electrophysiol20147338439124591540
   PubMed Web of Science ®Google Scholar
• JensenKGJuulKFink-JensenACorrellCUPagsbergAKCorrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trialsJ Am Acad Child Adolesc Psychiatry2015541253625524787
   PubMed Web of Science ®Google Scholar
• YangFDWangXQLiuXPSex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychoticsPsychopharmacology (Berl)2011216191621301815
   PubMed Web of Science ®Google Scholar
• ZhaiDLangYDongGQTc interval lengthening in first-episode schizophrenia (FES) patients in the earliest stages of antipsychotic treatmentSchizophr Res2017179707427727006
   PubMed Web of Science ®Google Scholar
• WuCSTsaiYTTsaiHJAntipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover studyJ Am Heart Assoc201542
   Web of Science ®Google Scholar
• LinderJRSodhiSKHaynesWGFiedorowiczJGEffects of antipsychotic drugs on cardiovascular variability in participants with bipolar disorderHum Psychopharmacol201429214515124590543
   PubMed Web of Science ®Google Scholar
• EbrahimzadehEPooyanMBijarAA novel approach to predict sudden cardiac death (SCD) using nonlinear and time-frequency analyses from HRV signalsPLoS One201492e8189624504331
   PubMed Web of Science ®Google Scholar
• CitromeLBrexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Int J Clin Pract201569997899726250067
   PubMed Web of Science ®Google Scholar
• PotkinSGPreskornSHochfeldMMengXA thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidoneJ Clin Psychopharmacol201333131023277250
   PubMed Web of Science ®Google Scholar
• CitromeLCariprazine for the treatment of schizophrenia: a review of this dopamine D3-preferring D3/D2 receptor partial agonistClin Schizophr Relat Psychoses201610210911927440212
   PubMedGoogle Scholar
• GuggerJJAntipsychotic pharmacotherapy and orthostatic hypotension: identification and managementCNS Drugs201125865967121790209
   PubMed Web of Science ®Google Scholar
• NourianZMowTMufticDOrthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor functionPsychopharmacology (Berl)20081991152718542932
   PubMed Web of Science ®Google Scholar
• RonaldsonKJFitzgeraldPBMcNeilJJEvolution of troponin, C-reactive protein and eosinophil count with the onset of clozapine-induced myocarditisAust N Z J Psychiatry201549548648725586749
   PubMed Web of Science ®Google Scholar
• WassefNKhanNMunirSQuetiapine-induced myocarditis presenting as acute STEMIBMJ Case Rep20152015
   Google Scholar
• Roesch-ElyDVan EinsiedelRKathoferSSchwaningerMWeisbrodMMyocarditis with quetiapineAm J Psychiatry2002159916071608
   PubMed Web of Science ®Google Scholar
• NielsenJCorrellCUManuPKaneJMTermination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?J Clin Psychiatry2013746603613 quiz 61323842012
   PubMed Web of Science ®Google Scholar
• ManuPSarpalDMuirOKaneJMCorrellCUWhen can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literatureSchizophr Res20121342–318018622113154
   PubMed Web of Science ®Google Scholar
• YoussefDLNarayananPGillNIncidence and risk factors for clozapine-induced myocarditis and cardiomyopathy at a regional mental health service in AustraliaAustralas Psychiatry201624217618026400457
   PubMed Web of Science ®Google Scholar
• WuQKlingJMDepression and the risk of myocardial infarction and coronary death: a meta-analysis of prospective cohort studiesMedicine (Baltimore)2016956e281526871852
   PubMed Web of Science ®Google Scholar
• PrietoMLCuellar-BarbozaABBoboWVRisk of myocardial infarction and stroke in bipolar disorder: a systematic review and exploratory meta-analysisActa Psychiatr Scand2014130534235324850482
   PubMed Web of Science ®Google Scholar
• FanZWuYShenJJiTZhanRSchizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studiesJ Psychiatr Res201347111549155623953755
   PubMed Web of Science ®Google Scholar
• LiMFanYLTangZYChengXSSchizophrenia and risk of stroke: a meta-analysis of cohort studiesInt J Cardiol2014173358859024698235
   PubMed Web of Science ®Google Scholar
• HsuWEsmaily-FardALeeCAntipsychotic exposure and risk of stroke: a systematic review and meta-analysis of observational studiesValue Health2015187A828
   Web of Science ®Google Scholar
• YuZHJiangHYShaoLZhouYYShiHYRuanBUse of antipsychotics and risk of myocardial infarction: a systematic review and meta-analysisBr J Clin Pharmacol201682362463227198162
   PubMed Web of Science ®Google Scholar
• JacksonJWSchneeweissSVanderWeeleTJBlackerDQuantifying the role of adverse events in the mortality difference between first and second-generation antipsychotics in older adults: systematic review and meta-synthesisPLoS One201498e10537625140533
   PubMed Web of Science ®Google Scholar
• ShinJYChoiNKJungSYLeeJKwonJSParkBJRisk of ischemic stroke with the use of risperidone, quetiapine and olanzapine in elderly patients: a population-based, case-crossover studyJ Psychopharmacol201327763864423535349
   PubMed Web of Science ®Google Scholar
• ShinJ-YChoiN-KLeeJRisk of ischemic stroke associated with the use of antipsychotic drugs in elderly patients: a retrospective cohort study in KoreaPLoS One2015103e011993125790285
   PubMed Web of Science ®Google Scholar
• PasternakBSvanstromHRantheMFMelbyeMHviidAAtypical antipsychotics olanzapine, quetiapine, and risperidone and risk of acute major cardiovascular events in young and middle-aged adults: a nationwide register-based cohort study in DenmarkCNS Drugs2014281096397324895158
   PubMed Web of Science ®Google Scholar
• LaytonDHarrisSWiltonLVShakirSAComparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementiaJ Psychopharmacol200519547348216166184
   PubMed Web of Science ®Google Scholar
• CorrellCUJoffeBIRosenLMSullivanTBJoffeRTCardiovascular and cerebrovascular risk factors and events associated with second-generation antipsychotic compared to antidepressant use in a non-elderly adult sample: results from a claims-based inception cohort studyWorld Psychiatry2015141566325655159
   PubMed Web of Science ®Google Scholar
• Bou KhalilRAtypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societiesClin Neuropharmacol201235314114722592510
   PubMed Web of Science ®Google Scholar
• MorissettePHreicheRMalletLVoDKnausEETurgeonJOlanzapine prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium currentJ Psychopharmacol200721773574117092964
   PubMed Web of Science ®Google Scholar
• GluaisPBastideMGrandmouginDFayadGAdamantidisMRisperidone reduces K+ currents in human atrial myocytes and prolongs repolarization in human myocardiumEur J Pharmacol2004497221522215306207
   PubMed Web of Science ®Google Scholar
• ShigaTYongSCarinoJMurrayPADamronDSDroperidol inhibits intracellular Ca2+, myofilament Ca2+ sensitivity, and contraction in rat ventricular myocytesAnesthesiology200510261165117315915029
   PubMed Web of Science ®Google Scholar
• HungGCLiuHCYangSYAntipsychotic reexposure and recurrent pneumonia in schizophrenia: a nested case-control studyJ Clin Psychiatry2016771606626613551
   PubMed Web of Science ®Google Scholar
• YangSYLiaoYTLiuHCChenWJChenCCKuoCJAntipsychotic drugs, mood stabilizers, and risk of pneumonia in bipolar disorder: a nationwide case-control studyJ Clin Psychiatry2013741e79e8623419234
   PubMed Web of Science ®Google Scholar
• HinkesRQuesadaTVCurrierMBGonzalez-BlancoMAspiration pneumonia possibly secondary to clozapine-induced sialorrheaJ Clin Psychopharmacol19961664624638959476
   PubMed Web of Science ®Google Scholar
• GambassiGSultanaJTrifiroGAntipsychotic use in elderly patients and the risk of pneumoniaExpert Opin Drug Saf20151411625431005
   PubMed Web of Science ®Google Scholar
• MehtaSPulunganZJonesBTTeiglandCComparative safety of atypical antipsychotics and the risk of pneumonia in the elderlyPharmacoepidemiol Drug Saf201524121271128026445931
   PubMed Web of Science ®Google Scholar
• NoseMReclaETrifiroGBarbuiCAntipsychotic drug exposure and risk of pneumonia: a systematic review and meta-analysis of observational studiesPharmacoepidemiol Drug Saf201524881282026017021
   PubMed Web of Science ®Google Scholar
• JacksonJWVanderWeeleTJBlackerDSchneeweissSMediators of first- versus second-generation antipsychotic-related mortality in older adultsEpidemiology201526570070926035686
   PubMed Web of Science ®Google Scholar
• StubbsBVancampfortDVeroneseNThe prevalence and predictors of obstructive sleep apnea in major depressive disorder, bipolar disorder and schizophrenia: a systematic review and meta-analysisJ Affect Disord201619725926726999550
   PubMed Web of Science ®Google Scholar
• OudMJMeyboom-de JongBSomatic diseases in patients with schizophrenia in general practice: their prevalence and health careBMC Fam Pract2009103219426545
   PubMed Web of Science ®Google Scholar
• WangMTTsaiCLLinCWYehCBWangYHLinHLAssociation between antipsychotic agents and risk of acute respiratory failure in patients with chronic obstructive pulmonary diseaseJAMA Psychiatry201774325226028055066
   PubMed Web of Science ®Google Scholar
• MinnsABClarkRFToxicology and overdose of atypical antipsy-choticsJ Emerg Med201243590691322555052
   PubMed Web of Science ®Google Scholar
• RishiMAShettyMWolffAAmoateng-AdjepongYManthousCAAtypical antipsychotic medications are independently associated with severe obstructive sleep apneaClin Neuropharmacol201033310911320502129
   PubMed Web of Science ®Google Scholar
• ChowVReddelCPenningsGGlobal hypercoagulability in patients with schizophrenia receiving long-term antipsychotic therapySchizophr Res20151621–317518225634682
   PubMed Web of Science ®Google Scholar
• ContiVVenegoniMCocciAFortinoILoraABarbuiCAntipsychotic drug exposure and risk of pulmonary embolism: a population-based, nested case-control studyBMC Psychiatry2015159225924683
   PubMed Web of Science ®Google Scholar
• BarbuiCContiVCiprianiAAntipsychotic drug exposure and risk of venous thromboembolism: a systematic review and meta-analysis of observational studiesDrug Saf2014372799024403009
   PubMed Web of Science ®Google Scholar
• ParkerCCouplandCHippisley-CoxJAntipsychotic drugs and risk of venous thromboembolism: nested case-control studyBMJ2010341c424520858909
   PubMed Web of Science ®Google Scholar
• ParkinLSkeggDCHerbisonGPPaulCPsychotropic drugs and fatal pulmonary embolismPharmacoepidemiol Drug Saf200312864765214762980
   PubMed Web of Science ®Google Scholar
• Every-PalmerSNowitzMStanleyJClozapine-treated patients have marked gastrointestinal hypomotility, the probable basis of life-threatening gastrointestinal complications: a cross sectional studyEBioMedicine20165125134
   PubMed Web of Science ®Google Scholar
• OzbilenMAdamsCEMarleyJAnticholinergic effects of oral antipsychotic drugs of typicals versus atypicals over medium- and long-term: systematic review and meta-analysisCurr Med Chem201219305214521823016549
   PubMed Web of Science ®Google Scholar
• StubbsBThompsonTAcasterSVancampfortDGaughranFCorrellCUDecreased pain sensitivity among people with schizophrenia: a meta-analysis of experimental pain induction studiesPain2015156112121213126207650
   PubMed Web of Science ®Google Scholar
• ShiraziAStubbsBGomezLPrevalence and predictors of clozapine-associated constipation: a systematic review and meta-analysisInt J Mol Sci2016176
   PubMed Web of Science ®Google Scholar
• HarringtonCAEnglishCTolerability of paliperidone: a meta-analysis of randomized, controlled trialsInt Clin Psychopharmacol201025633434120706126
   PubMed Web of Science ®Google Scholar
• GallingBRoldanARietschelLSafety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trialsExpert Opin Drug Saf201615559161226967126
   PubMed Web of Science ®Google Scholar
• FleischhackerWWSanchezRJohnsonBLong-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophreniaInt Clin Psychopharmacol201328417117623615694
   PubMed Web of Science ®Google Scholar
• CitromeLCariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapyAdv Ther201330211412623361833
   PubMed Web of Science ®Google Scholar
• HuKFChouYHWenYHAntipsychotic medications and dental caries in newly diagnosed schizophrenia: a nationwide cohort studyPsychiatry Res2016245455027526316
   PubMed Web of Science ®Google Scholar
• LiXBTangYLWangCYde LeonJClozapine for treatment-resistant bipolar disorder: a systematic reviewBipolar Disord201517323524725346322
   PubMed Web of Science ®Google Scholar
• MarwickKFTaylorMWalkerSWAntipsychotics and abnormal liver function tests: systematic reviewClin Neuropharmacol201235524425322986798
   PubMed Web of Science ®Google Scholar
• AtasoyNErdoganAYalugIA review of liver function tests during treatment with atypical antipsychotic drugs: a chart review studyProg Neuropsychopharmacol Biol Psychiatry20073161255126017600607
   PubMed Web of Science ®Google Scholar
• DumortierGCabaretWStamatiadisLTolérance hépatique des antipsychotiques atypiques [Hepatic tolerance of atypical antipsychotic drugs]Encephale2002286 pt 154255112506267
   PubMed Web of Science ®Google Scholar
• HsuJHChienICLinCHIncreased risk of chronic liver disease in patients with bipolar disorder: a population-based studyGen Hosp Psychiatry201642545927638973
   PubMed Web of Science ®Google Scholar
• Morlan-CoarasaMJArias-LosteMTOrtiz-Garcia de la FozVIncidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional studyPsychopharmacology (Berl)201623323–243947395227620899
   PubMed Web of Science ®Google Scholar
• SlimMMedina-CalizIGonzalez-JimenezAHepatic safety of atypical antipsychotics: current evidence and future directionsDrug Saf2016391092594327449495
   PubMed Web of Science ®Google Scholar
• FountoulakisKNGrunzeHVietaEThe International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelinesInt J Neuropsychopharmacol201720298120
   PubMed Web of Science ®Google Scholar
• ScarffJRCariprazine for schizophrenia and bipolar disorderInnov Clin Neurosci2016139–10495227975000
   PubMedGoogle Scholar
• Faure WalkerNBrinchmannKBaturaDLinking the evidence between urinary retention and antipsychotic or antidepressant drugs: a systematic reviewNeurourol Urodyn201635886687426288221
   PubMed Web of Science ®Google Scholar
• HwangYJDixonSNReissJPAtypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort studyAnn Intern Med2014161424224825133360
   PubMed Web of Science ®Google Scholar
• VerhammeKMSturkenboomMCStrickerBHBoschRDrug-induced urinary retention: incidence, management and preventionDrug Saf200831537338818422378
   PubMed Web of Science ®Google Scholar
• BarnesTRDrakeMJPatonCNocturnal enuresis with antipsychotic medicationBr J Psychiatry201220017922215862
   PubMed Web of Science ®Google Scholar
• GoodwinGMHaddadPMFerrierINEvidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for PsychopharmacologyJ Psychopharmacol201630649555326979387
   PubMed Web of Science ®Google Scholar
• BulutSDBulutSAtalanDGThe effect of antipsychotics on bone mineral density and sex hormones in male patients with schizophreniaPsychiatr Danub201628325526227658834
   PubMed Web of Science ®Google Scholar
• KishimotoTDe HertMCarlsonHEManuPCorrellCUOsteoporosis and fracture risk in people with schizophreniaCurr Opin Psychiatry201225541542922744405
   PubMed Web of Science ®Google Scholar
• StubbsBDe HertMSepehryAAA meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophreniaActa Psychiatr Scand2014130647048625041606
   PubMed Web of Science ®Google Scholar
• GomezLStubbsBShiraziAVancampfortDGaughranFLallyJLower bone mineral density at the hip and lumbar spine in people with psychosis versus controls: a comprehensive review and skeletal site-specific meta-analysisCurr Osteoporos Rep201614624925927696144
   PubMed Web of Science ®Google Scholar
• ZhangBDengLWuHRelationship between long-term use of a typical antipsychotic medication by Chinese schizophrenia patients and the bone turnover markers serum osteocalcin and beta-CrossLapsSchizophr Res20161762–325926327377977
   PubMed Web of Science ®Google Scholar
• De HertMDetrauxJStubbsBRelationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature reviewExpert Opin Drug Saf201615680982326986209
   PubMed Web of Science ®Google Scholar
• StubbsBGaughranFMitchellAJSchizophrenia and the risk of fractures: a systematic review and comparative meta-analysisGen Hosp Psychiatry201537212613325666994
   PubMed Web of Science ®Google Scholar
• TorstenssonMLeth-MollerKAnderssonCTorp-PedersenCGislasonGHHolmEADanish register-based study on the association between specific antipsychotic drugs and fractures in elderly individualsAge Ageing201746225826427932365
   PubMed Web of Science ®Google Scholar
• WeiYJSimoni-WastilaLLucasJABrandtNFall and fracture risk in nursing home residents with moderate-to-severe behavioral symptoms of Alzheimer’s disease and related dementias initiating antidepressants or antipsychoticsJ Gerontol A Biol Sci Med Sci2016725695702
   Web of Science ®Google Scholar
• BerrySDPlacideSGMostofskyEAntipsychotic and benzodiazepine drug changes affect acute falls risk differently in the nursing homeJ Gerontol A Biol Sci Med Sci201671227327826248560
   PubMed Web of Science ®Google Scholar
• KlugeMSchuldAHimmerichHClozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind studyJ Clin Psychopharmacol200727666266618004133
   PubMed Web of Science ®Google Scholar
• EtminanMSodhiMSamiiAProcyshynRMGuoMCarletonBCRisk of gambling disorder and impulse control disorder with aripiprazole, pramipexole, and ropinirole: a pharmacoepidemiologic studyJ Clin Psychopharmacol201737110210427930495
   PubMed Web of Science ®Google Scholar
• MooreTJGlenmullenJMattisonDRReports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugsJAMA Intern Med2014174121930193325329919
   PubMed Web of Science ®Google Scholar
• GaboriauLVictorri-VigneauCGerardinMAllain-VeyracGJolliet-EvinPGrall-BronnecMAripiprazole: a new risk factor for pathological gambling? A report of 8 case reportsAddict Behav201439356256524315783
   PubMed Web of Science ®Google Scholar
• FriedmanJHBermanRMGoetzCGOpen-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson’s diseaseMov Disord200621122078208117013906
   PubMed Web of Science ®Google Scholar
• Grall-BronnecMSauvagetAPerrouinFPathological gambling associated with aripiprazole or dopamine replacement therapy: do patients share the same features? A ReviewJ Clin Psychopharmacol2016361637026658263
   PubMed Web of Science ®Google Scholar
• WuBJChenHKLeeSMDo atypical antipsychotics really enhance smoking reduction more than typical ones? The effects of antipsychotics on smoking reduction in patients with schizophreniaJ Clin Psychopharmacol201333331932823609378
   PubMed Web of Science ®Google Scholar
• WuBJLanTHPredictors of smoking reduction outcomes in a sample of 287 patients with schizophrenia spectrum disordersEur Arch Psychiatry Clin Neurosci20172671637226310877
   PubMed Web of Science ®Google Scholar
• HeffnerJLStrawnJRDelBelloMPStrakowskiSMAnthenelliRMThe co-occurrence of cigarette smoking and bipolar disorder: phenomenology and treatment considerationsBipolar Disord2011135–643945322017214
   PubMed Web of Science ®Google Scholar
• FeatherstoneRESiegelSJThe role of nicotine in schizophreniaInt Rev Neurobiol2015124237826472525
   PubMed Web of Science ®Google Scholar
• GallegoJANielsenJDe HertMKaneJMCorrellCUSafety and tolerability of antipsychotic polypharmacyExpert Opin Drug Saf201211452754222563628
   PubMed Web of Science ®Google Scholar
• LeeJYKimSWLeeYHFactors associated with self-rated sexual function in Korean patients with schizophrenia receiving risperidone monotherapyHum Psychopharmacol201530641642426123060
   PubMed Web of Science ®Google Scholar
• WirshingDAPierreJMMarderSRSaundersCSWirshingWCSexual side effects of novel antipsychotic medicationsSchizophr Res2002561–2253012084416
   PubMed Web of Science ®Google Scholar
• MontejoALMontejoLNavarro-CremadesFSexual side-effects of antidepressant and antipsychotic drugsCurr Opin Psychiatry201528641842326382168
   PubMed Web of Science ®Google Scholar
• PacchiarottiILeon-CaballeroJMurruAMood stabilizers and antipsychotics during breastfeeding: focus on bipolar disorderEur Neuropsychopharmacol201626101562157827568278
   PubMed Web of Science ®Google Scholar
• ComptonMTMillerAHAntipsychotic-induced hyperprolactinemia and sexual dysfunctionPsychopharmacol Bull200236114316412397853
   PubMedGoogle Scholar
• ComptonMTMillerAHPriapism associated with conventional and atypical antipsychotic medications: a reviewJ Clin Psychiatry200162536236611411819
   PubMed Web of Science ®Google Scholar
• LohCLeckbandSGMeyerJMTurnerERisperidone-induced retrograde ejaculation: case report and review of the literatureInt Clin Psychopharmacol200419211111215076020
   PubMed Web of Science ®Google Scholar
• JustMJThe influence of atypical antipsychotic drugs on sexual functionNeuropsychiatr Dis Treat2015111655166126185449
   PubMed Web of Science ®Google Scholar
• JinHMeyerJMJesteDVPhenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published casesAnn Clin Psychiatry2002141596412046641
   PubMedGoogle Scholar
• PolcwiartekCVangTBruhnCHHashemiNRosenzweigMNielsenJDiabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reportsPsychopharmacology (Berl)201623321–223663367227592232
   PubMed Web of Science ®Google Scholar
• LambertCGMazurieAJLauveNRHypothyroidism risk compared among nine common bipolar disorder therapies in a large US cohortBipolar Disord201618324726027226264
   PubMed Web of Science ®Google Scholar
• KellyDLConleyRRThyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazineJ Clin Psychiatry2005661808415669892
   PubMed Web of Science ®Google Scholar
• MannesseCKvan PuijenbroekEPJansenPAvan MarumRJSouvereinPCEgbertsTCHyponatraemia as an adverse drug reaction of antipsychotic drugs: a case-control study in VigiBaseDrug Saf201033756957820553058
   PubMed Web of Science ®Google Scholar
• YamadaKShinkaiTChenHIUtsunomiyaKNakamuraJEffect of COMT Val108/158Met genotype on risk for polydipsia in chronic patients with schizophreniaNeuromolecular Med201416239840424443099
   PubMed Web of Science ®Google Scholar
• TsuboiTBiesRRSuzukiTHyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE dataProg Neuropsychopharmacol Biol Psychiatry20134517818223727135
   PubMed Web of Science ®Google Scholar
• CarboniLNegriMMichielinFSlow dissociation of partial agonists from the D(2) receptor is linked to reduced prolactin releaseInt J Neuropsychopharmacol201215564565621733233
   PubMed Web of Science ®Google Scholar
• MontejoALArangoCBernardoMSpanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemiaRev Psiquiatr Salud Ment20169315817326927534
   PubMed Web of Science ®Google Scholar
• PacchiarottiIMurruAKotzalidisGDHyperprolactinemia and medications for bipolar disorder: systematic review of a neglected issue in clinical practiceEur Neuropsychopharmacol20152581045105925937241
   PubMed Web of Science ®Google Scholar
• ChenJXSuYABianQTAdjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized, double-blind, placebo-controlled, dose-response studyPsychoneuroendocrinology20155813014025981348
   PubMed Web of Science ®Google Scholar
• ChenCYLinTYWangCCShuaiHAImprovement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case seriesPsychiatry Clin Neurosci2011651959721265942
   PubMed Web of Science ®Google Scholar
• MelkerssonKHultingALProlactin-secreting pituitary adenoma in neuroleptic treated patients with psychotic disorderEur Arch Psychiatry Clin Neurosci2000250161010738858
   PubMed Web of Science ®Google Scholar
• PerroudNHugueletPA possible effect of amisulpride on a prolactinoma growth in a woman with borderline personality disorderPharmacol Res200450337737915225684
   PubMed Web of Science ®Google Scholar
• AkkayaCKayaBKotanZSarandolAErsoyCKirliSHyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three casesJ Psychopharmacol200923672372618562408
   PubMed Web of Science ®Google Scholar
• PalJKSarinoWAEffect of risperidone on prolactinoma growth in a psychotic womanPsychosom Med200062573673811020104
   PubMed Web of Science ®Google Scholar
• MendhekarDNJilohaRCSrivastavaPKEffect of risperidone on prolactinoma – a case reportPharmacopsychiatry2004371414214750048
   PubMed Web of Science ®Google Scholar
• ArcariGTMendesAKSothernRBA risperidone-induced prolactinoma resolved when a woman with schizoaffective disorder switched to ziprasidone: a case reportInnov Clin Neurosci2012992124
   PubMedGoogle Scholar
• MontejoALArangoCBernardoMMultidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychoticsFront Neuroendocrinol201745253428235557
   PubMed Web of Science ®Google Scholar
• BallerJBMcGintyEEAzrinSTJuliano-BultDDaumitGLScreening for cardiovascular risk factors in adults with serious mental illness: a review of the evidenceBMC Psychiatry2015155525885367
   PubMed Web of Science ®Google Scholar
• MoPKMakWWChongESShenHCheungRYThe prevalence and factors for cancer screening behavior among people with severe mental illness in Hong KongPLoS One201499e10723725268752
   PubMed Web of Science ®Google Scholar
• RibeARLaurbergTLaursenTMCharlesMVedstedPVestergaardMTen-year mortality after a breast cancer diagnosis in women with severe mental illness: a Danish population-based cohort studyPLoS One2016117e015801327462907
   PubMed Web of Science ®Google Scholar
• OsbornDPLevyGNazarethIPetersenIIslamAKingMBRelative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom’s General Practice Rsearch DatabaseArch Gen Psychiatry200764224224917283292
   PubMed Web of Science ®Google Scholar
• JiJSundquistKNingYKendlerKSSundquistJChenXIncidence of cancer in patients with schizophrenia and their first-degree relatives: a population-based study in SwedenSchizophr Bull201339352753622522642
   PubMed Web of Science ®Google Scholar
• De HertMVancampfortDStubbsBSabbeTWildiersHDetrauxJAntipsychotic treatment, prolactin, and breast tumorigenesisPsychiatr Danub201628324325427658833
   PubMed Web of Science ®Google Scholar
• De HertMPeuskensJSabbeTRelationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical reviewActa Psychiatr Scand2016133152226114737
   PubMed Web of Science ®Google Scholar
• ReutforsJWingardLBrandtLRisk of breast cancer in risperidone users: a nationwide cohort studySchizophr Res20171829810327823949
   PubMed Web of Science ®Google Scholar
• FondGMacgregorAAttalJAntipsychotic drugs: pro-cancer or anti-cancer? A systematic reviewMed Hypotheses2012791384222543071
   PubMed Web of Science ®Google Scholar
• CaroffSNThe neuroleptic malignant syndromeJ Clin Psychiatry198041379836101595
   PubMed Web of Science ®Google Scholar
• GurreraRJSimpsonJCTsuangMTMeta-analytic evidence of systematic bias in estimates of neuroleptic malignant syndrome incidenceCompr Psychiatry200748220521117292713
   PubMed Web of Science ®Google Scholar
• TseLBarrAMScarapicchiaVVila-RodriguezFNeuroleptic malignant syndrome: a review from a clinically oriented perspectiveCurr Neuropharmacol201513339540626411967
   PubMed Web of Science ®Google Scholar
• Belvederi MurriMGuaglianoneABuglianiMSecond-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysisDrugs R D2015151456225578944
   PubMed Web of Science ®Google Scholar
• NeuhutRLindenmayerJPSilvaRNeuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: a reviewJ Child Adolesc Psychopharmacol200919441542219702493
   PubMed Web of Science ®Google Scholar
• WeinmannSReadJAderholdVInfluence of antipsychotics on mortality in schizophrenia: systematic reviewSchizophr Res2009113111119524406
   PubMed Web of Science ®Google Scholar
• SeemanPTargeting the dopamine D2 receptor in schizophreniaExpert Opin Ther Targets200610451553116848689
   PubMed Web of Science ®Google Scholar
• CeroveckiAMusilRKlimkeAWithdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendationsCNS Drugs201327754557223821039
   PubMed Web of Science ®Google Scholar
• GentileSAntipsychotic therapy during early and late pregnancy. A systematic reviewSchizophr Bull201036351854418787227
   PubMed Web of Science ®Google Scholar
• HabermannFFritzscheJFuhlbruckFAtypical antipsychotic drugs and pregnancy outcome: a prospective, cohort studyJ Clin Psychopharmacol201333445346223764684
   PubMed Web of Science ®Google Scholar
• VigodSNGomesTWiltonASTaylorVHRayJGAntipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort studyBMJ2015350h229825972273
   PubMed Web of Science ®Google Scholar
• LarsenERDamkierPPedersenLHUse of psychotropic drugs during pregnancy and breast-feedingActa Psychiatr Scand Suppl2015132445128
   Google Scholar
• HuybrechtsKFHernandez-DiazSPatornoEAntipsychotic use in pregnancy and the risk for congenital malformationsJAMA Psychiatry201673993894627540849
   PubMed Web of Science ®Google Scholar
• CohrsSSleep disturbances in patients with schizophrenia: impact and effect of antipsychoticsCNS Drugs2008221193996218840034
   PubMed Web of Science ®Google Scholar
• KreuzerPLandgrebeMWittmannMHypothermia associated with antipsychotic drug use: a clinical case series and review of current literatureJ Clin Pharmacol20125271090109721956608
   PubMed Web of Science ®Google Scholar
• KaneJMCorrellCUPast and present progress in the pharmacologic treatment of schizophreniaJ Clin Psychiatry20107191115112420923620
   PubMed Web of Science ®Google Scholar
• CorrellCUAcute and long-term adverse effects of antipsychoticsCNS Spectr20071212 suppl 211014
   PubMed Web of Science ®Google Scholar
• CaemmererJCorrellCUMaayanLAcute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: a meta-analytic comparison of randomized controlled trialsSchizophr Res20121401–315916822763424
   PubMed Web of Science ®Google Scholar
• MizunoYSuzukiTNakagawaAPharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysisSchizophr Bull20144061385140324636967
   PubMed Web of Science ®Google Scholar
• PearsallRThyarappa PraveenKPelosiAGeddesJDietary advice for people with schizophreniaCochrane Database Syst Rev20163CD00954727007216
   PubMed Web of Science ®Google Scholar
• PearsallRSmithDJPelosiAGeddesJExercise therapy in adults with serious mental illness: a systematic review and meta-analysisBMC Psychiatry20141411724751159
   PubMed Web of Science ®Google Scholar
• GierischJMNieuwsmaJABradfordDWPharmacologic and behavioral interventions to improve cardiovascular risk factors in adults with serious mental illness: a systematic review and meta-analysisJ Clin Psychiatry2014755e424e44024922495
   PubMed Web of Science ®Google Scholar
• SpeyerHChristian Brix NorgaardHBirkMThe CHANGE trial: no superiority of lifestyle coaching plus care coordination plus treatment as usual compared to treatment as usual alone in reducing risk of cardiovascular disease in adults with schizophrenia spectrum disorders and abdominal obesityWorld Psychiatry201615215516527265706
   PubMed Web of Science ®Google Scholar
• StahlSMMallaANewcomerJWA post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trialJ Clin Psychopharmacol201030442543020571437
   PubMed Web of Science ®Google Scholar
• ColomFVietaEDabanCPacchiarottiISanchez-MorenoJClinical and therapeutic implications of predominant polarity in bipolar disorderJ Affect Disord2006931–3131716650901
   PubMed Web of Science ®Google Scholar
• CalabreseJRHirschfeldRMFryeMAReedMLImpact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sampleJ Clin Psychiatry200465111499150415554762
   PubMed Web of Science ®Google Scholar
• GrandeIBerkMBirmaherBVietaEBipolar disorderLancet2016387100271561157226388529
   PubMed Web of Science ®Google Scholar
• PopovicDReinaresMGoikoleaJMBonninCMGonzalez-PintoAVietaEPolarity index of pharmacological agents used for maintenance treatment of bipolar disorderEur Neuropsychopharmacol201222533934622000157
   PubMed Web of Science ®Google Scholar
• CarvalhoAFQuevedoJMcIntyreRSTreatment implications of predominant polarity and the polarity index: a comprehensive reviewInt J Neuropsychopharmacol2014182
   PubMed Web of Science ®Google Scholar
• MurruAPacchiarottiIAmannBLNivoliAMVietaEColomFTreatment adherence in bipolar I and schizoaffective disorder, bipolar typeJ Affect Disord201315131003100824099884
   PubMed Web of Science ®Google Scholar
• RosaARAndreazzaACKunzMPredominant polarity in bipolar disorder: diagnostic implicationsJ Affect Disord20081071–3455117804081
   PubMed Web of Science ®Google Scholar
• GrunzeHVietaEGoodwinGMThe World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorderWorld J Biol Psychiatry201314315421923480132
   PubMed Web of Science ®Google Scholar
• HasanAFalkaiPWobrockTWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effectsWorld J Biol Psychiatry201314124423216388
   PubMed Web of Science ®Google Scholar
• BarnesTRSchizophrenia Consensus Group of British Association for P. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for PsychopharmacologyJ Psychopharmacol201125556762021292923
   PubMed Web of Science ®Google Scholar
• FleemanNDundarYDicksonRCytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analysesPharmacogenomics J201111111420877299
   PubMed Web of Science ®Google Scholar
• VietaELa medicina personalizada aplicada a la salud mental: la psiquiatría de precisión [Personalised medicine applied to mental health: precision psychiatry]Rev Psiquiatr Salud Ment20158311711825959401
   PubMed Web of Science ®Google Scholar